Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer

Journal of Urology - Netherlands
doi 10.1016/j.juro.2007.09.016
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Metastatic Renal Cell Cancer

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2013English

Recombinant Human Interleukin 6 in Metastatic Renal Cell Cancer: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
1996English

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Immunotherapy of Metastatic Renal Cell Cancer

Cancer Control
MedicineOncologyHematology
2002English

Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial

British Journal of Cancer
Cancer ResearchOncology
2011English

Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates

Clinical Genitourinary Cancer
OncologyUrology
2016English

Brain Complete Response to Cabozantinib Prior to Radiation Therapy in Metastatic Renal Cell Carcinoma

Case Reports in Urology
2019English

Intravenous Interleukin-2 in Patients Over 65 With Metastatic Renal Carcinoma

British Journal of Cancer
Cancer ResearchOncology
1992English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy